ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3‐ITD

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3‐ITD

Bromodomain‐containing protein 4 (BRD4) inhibitors have been clinically developed to treat acute myeloid leukemia (AML), but their application is limited by the possibility of drug resistance, which is reportedly associated with the activation of the WNT/β‐catenin pathway. Meanwhile, homoharringtoni...

Full description

Bibliographic Details
Main Authors:	Yu Qian, Xiang Zhang, Shihui Mao, Wenwen Wei, Xiangjie Lin, Qing Ling, Wenle Ye, Fenglin Li, Jiajia Pan, Yutong Zhou, Yanchun Zhao, Xin Huang, Jiansong Huang, Hongyan Tong, Jie Sun, Jie Jin
Format:	Article
Language:	English
Published:	Wiley 2023-07-01
Series:	Molecular Oncology
Subjects:	acute myeloid leukemia FLT3‐ITD homoharringtonine novel BRD4 Inhibitor ACC010
Online Access:	https://doi.org/10.1002/1878-0261.13368

Similar Items

FLT3 - ITD positive acute lymphocytic leukemia, does it impact on disease´s course?
by: Sebastian Kobold, et al.
Published: (2010-06-01)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
by: Mariko Takenokuchi, et al.
Published: (2012-10-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype
by: Irina Stepanovna Martynkevich, et al.
Published: (2010-12-01)

<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
by: Andrew Y. Li, et al.
Published: (2021-03-01)

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
by: Wenwen Wei, et al.
Published: (2022-07-01)

Comparison of high-resolution melting analysis with direct sequencing for detection of FLT3-TKD, FLT3-ITD and WT1 mutations in acute myeloid leukemia
by: Aida Mahmoudi, et al.
Published: (2021-01-01)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Dan Xu, et al.
Published: (2022-07-01)

Potential Effects of the FLT3-ITD Mutation on Chemotherapy Response and Prognosis of Acute Promyelocytic Leukemia
by: Song Y, et al.
Published: (2021-03-01)

Estudio del ratio de FLT3-ITD como factor pronóstico en leucemias agudas mieloides
by: Evangelina González, et al.
Published: (2016-09-01)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
by: Franziska Schmidt, et al.
Published: (2022-11-01)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
by: Xinhua Xiao, et al.
Published: (2023-11-01)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
by: Maximilian Fleischmann, et al.
Published: (2021-11-01)

Frequency of FLT3/ITD Mutation in Patients with Acute Myeloid Leukaemia presenting at Combined Military Hospital, Rawalpindi
by: Anil Babar, et al.
Published: (2023-12-01)

FLT3-ITD DNA allelic burden, but not mRNA levels, influences the biological characteristics of AML patients
by: Soare Dan S., et al.
Published: (2021-01-01)

Study of HOTAIR LncRNA in AML patients in context to FLT3-ITD and NPM1 mutations status
by: Mona Salah, et al.
Published: (2021-06-01)

Are cup-like blasts specific to AML patients with FLT3 ITD and a normal karyotype? An ALL case report and review of the literature
by: Özgür Mehtap, et al.
Published: (2011-06-01)

Are cup-like blasts specific to AML patients with FLT3 ITD and a normal karyotype? An ALL case report and review of the literature
by: Özgür Mehtap, et al.
Published: (2011-05-01)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
by: Caroline Engen, et al.
Published: (2021-09-01)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
by: Peihong Wang, et al.
Published: (2021-07-01)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
by: D Sorcini, et al.
Published: (2023-11-01)

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study
by: Hind Dehbi, et al.
Published: (2013-01-01)

Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation
by: Ya B Balzhanova, et al.
Published: (2019-08-01)

Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
by: Pimjai Niparuck, et al.
Published: (2019-01-01)

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
by: Takahiro Kumode, et al.
Published: (2020-01-01)

Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
by: Sankaranarayan Kannan, et al.
Published: (2022-04-01)

The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia
by: Masahiro Sakaguchi, et al.
Published: (2020-01-01)

Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD+ AML Cells
by: Panpan Feng, et al.
Published: (2022-05-01)

FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)
by: Luca Lo Nigro, et al.
Published: (2022-05-01)

FLT-3 ITD Positive Acute Basophilic Leukemia with Rare Complex Karyotype Presenting with Acute Respiratory Failure: Case Report
by: Antohe Ion, et al.
Published: (2018-01-01)

ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
by: Doh Yu Hwang, et al.
Published: (2020-05-01)

Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
by: Katagiri S, et al.
Published: (2023-07-01)

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial
by: Chengtao Zhang, et al.
Published: (2023-08-01)

NPM1 and FLT3-(ITD) Gene mutations and laboratory findings in patients with acute myeloid leukemia in Northwest of Iran
by: Sanaat Z, et al.
Published: (2014-10-01)

Hsa_circ_0015278 Regulates FLT3-ITD AML Progression via Ferroptosis-Related Genes
by: Jiquan Jiang, et al.
Published: (2022-12-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
by: Belen Lopez-Millan, et al.
Published: (2022-03-01)

Discovery of 5-methyl-N-(2-arylquinazolin-7-yl)isoxazole-4-carboxamide analogues as highly selective FLT3 inhibitors
by: Daseul Im, et al.
Published: (2020-01-01)

Role of Biomarkers in FLT3 AML
by: Nitika, et al.
Published: (2022-02-01)

Evaluation of cytokines and soluble adhesion molecules in patients with newly diagnosed acute myeloid leukemia: the role of TNF-alpha and FLT3-ITD
by: Tomas Kupsa, et al.
Published: (2016-03-01)